Can-Fite BioPharma Successfully Concludes $6,000,000 Public Offering With an Over-Subscription of 300%

Company Expects to Apply to List Its U.S. ADRs on the NYSE MKT

Continue Reading

Nutra Pharma Announces Updated Interviews With Wall Street Buy Sell Hold

Nutra Pharma Is Announcing an Updated Interview With Chris Castaldo and Wall Street Buy Sell Hold

Continue Reading

Can-Fite BioPharma-s CF101 Drug Selected as one of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence

CF101 Is Currently in Phase III Trials for Psoriasis and Phase II for Rheumatoid Arthritis

Continue Reading

Can-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece

Phase II Trial to Commence Under FDA Orphan Drug Designation

Continue Reading

Can-Fite-s Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum

To Showcase Clinical Data on CF101 for Treatment of Glaucoma

Continue Reading

Can-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com

PETACH TIKVA, ISRAEL -- (Marketwired) -- 09/23/13 -- (TASE: CFBI), (PINKSHEETS: CANFY), a biotechnology company with…

Continue Reading

MIT Holding, Inc. (MITD) Announces Negotiations With Leading Private Duty Care and Services Company

SAVANNA, GA -- (Marketwired) -- 08/16/13 -- . (OTCQB: MITD) announces that it has begun negotiations…

Continue Reading